Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

66.16
Delayed Data
As of Feb 24
 +0.31 / +0.47%
Today’s Change
49.63
Today|||52-Week Range
66.16
+12.38%
Year-to-Date
Merck Takes $2.9 Billion Charge on Dampened Outlook for Hepatitis Drug
Feb 24 / TheStreet.com - Paid Partner Content
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
Feb 16 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, No...
Feb 24 / Zacks.com - Paid Partner Content
Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?
Feb 15 / MotleyFool.com - Paid Partner Content
Why 3D Printing and Biotech Will Be Good Bets in 2017
Feb 23 / GuruFocus News - Paid Partner Content
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
Feb 15 / Zacks.com - Paid Partner Content
Trump Meets With Top CEOs To Brainstorm "Jump-Starting" US Economy, Creating Jobs
Feb 23 / Investing Channel - Paid Partner Content
Merck's drug failure deals further blow to Alzheimer's theory
Feb 15 / FT.com - Paid Partner Content
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Feb 22 / TheStreet.com - Paid Partner Content
Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip
Feb 15 / Zacks.com - Paid Partner Content
Bristol Myers' Future Unsure as Carl Icahn Takes Stake
Feb 22 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Coca-Cola, Walt Disney, Visa, Boeing and Merck
Feb 13 / Zacks.com - Paid Partner Content
House Border Tax Plan Could Make Travel Abroad Cheaper for Americans
Feb 22 / TheStreet.com - Paid Partner Content
Brakes on the pathway to treating cancer
Feb 09 / FT.com - Paid Partner Content
Can Carl Icahn Save Bristol Myers Squibb?
Feb 21 / Zacks.com - Paid Partner Content
Publicis hit by Razorfish impairment and slower US revenues
Feb 09 / FT.com - Paid Partner Content
Bristol-Myers Buys Back Shares, Shuffles Board
Feb 21 / TheStreet.com - Paid Partner Content
AstraZeneca: faith healer
Feb 02 / FT.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Alle...
Feb 21 / Zacks.com - Paid Partner Content
Merck hails rise in patient tests for immunotherapy drug Keytruda
Feb 02 / FT.com - Paid Partner Content
Better Buy: Pfizer Inc. vs. Merck & Co. Inc.
Feb 21 / MotleyFool.com - Paid Partner Content
Pharma stocks rally on Trump pledge to speed drug approvals
Feb 02 / FT.com - Paid Partner Content
US exporters line up behind tax code overhaul
Feb 21 / FT.com - Paid Partner Content
Earnings deluge; Trump diplomacy; Takeover time?
Feb 02 / CNNMoney.com
The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign an...
Feb 17 / Zacks.com - Paid Partner Content
 Pharma execs tout 'manufacturing jobs' in front of Trump
Jan 31 / CNNMoney.com
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
Feb 17 / Zacks.com - Paid Partner Content
CEOs cheat sheet on how to please Trump
Jan 31 / CNNMoney.com
Q4 Earnings Season Scorecard & Top Analyst Reports
Feb 16 / Zacks.com - Paid Partner Content
Johnson & Johnson's $30B takeover keeps cash overseas
Jan 26 / CNNMoney.com
What's Driving Lilly's (LLY) Shares after 2016 Decline?
Feb 16 / Zacks.com - Paid Partner Content